In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography
Journal Article
·
· J. Nucl. Med.; (United States)
OSTI ID:6558225
Carbon-11 thymidine (TdR) uptake using positron emission tomography (PET) has been measured in ten patients with non-Hodgkin's lymphoma (NHL). The rate of TdR uptake (mean +/- s.d.) was of 0.009 +/- 0.006 mumol.100 cc-1.min-1 in low-grade NHL. This rate was 0.063 +/- 0.049 mumol.100 cc-1.min-1 in intermediate-grade NHL and 0.159 mumol.100 cc-1.min-1 in a patient with high-grade NHL. Lymphoma radioactivity reached a plateau at 0.42 +/- 0.22%. 100 cc-1 of the injected dose from 10 min after injection. The highest /sup 11/C uptakes were observed in the kidneys and in the liver (3.30 +/- 1.30 and 2.10 +/- 0.05%. 100 cc-1 of the injected dose, respectively). The lymphoma-to-muscle ratio was of 11.8 +/- 1.7, whereas the lymphoma-to-intestine ratio was of 1.5 +/- 0.7. Accordingly, the measurement of (/sup 11/C)TdR uptake in the abdomen may need other imaging methods for adequate interpretation. The results suggest that (/sup 11/C)TdR uptake using PET might be a method for noninvasively measuring cell proliferation in vivo.
- Research Organization:
- Univ. of Louvain, Medical School, Brussels (Belgium)
- OSTI ID:
- 6558225
- Journal Information:
- J. Nucl. Med.; (United States), Journal Name: J. Nucl. Med.; (United States) Vol. 29:10; ISSN JNMEA
- Country of Publication:
- United States
- Language:
- English
Similar Records
Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: A PET study
Radioimmunodetection of non-Hodgkin`s lymphoma with radiolabelled LL2 monoclonal antibody. Preliminary results
Combined Modality Treatment for PET-Positive Non-Hodgkin Lymphoma: Favorable Outcomes of Combined Modality Treatment for Patients With Non-Hodgkin Lymphoma and Positive Interim or Postchemotherapy FDG-PET
Journal Article
·
Sat Jun 01 00:00:00 EDT 1991
· Journal of Nuclear Medicine; (United States)
·
OSTI ID:5594459
Radioimmunodetection of non-Hodgkin`s lymphoma with radiolabelled LL2 monoclonal antibody. Preliminary results
Journal Article
·
Sun May 01 00:00:00 EDT 1994
· Journal of Nuclear Medicine
·
OSTI ID:197960
Combined Modality Treatment for PET-Positive Non-Hodgkin Lymphoma: Favorable Outcomes of Combined Modality Treatment for Patients With Non-Hodgkin Lymphoma and Positive Interim or Postchemotherapy FDG-PET
Journal Article
·
Wed Aug 01 00:00:00 EDT 2012
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:22149407
Related Subjects
550601* -- Medicine-- Unsealed Radionuclides in Diagnostics
62 RADIOLOGY AND NUCLEAR MEDICINE
AZINES
BETA DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
CARBON 11
CARBON ISOTOPES
CELL PROLIFERATION
COMPUTERIZED TOMOGRAPHY
DIAGNOSIS
DIAGNOSTIC TECHNIQUES
DISEASES
DISTRIBUTION
EMISSION COMPUTED TOMOGRAPHY
EVEN-ODD NUCLEI
HETEROCYCLIC COMPOUNDS
IMMUNE SYSTEM DISEASES
IN VIVO
ISOTOPES
LIGHT NUCLEI
LYMPHOMAS
MINUTES LIVING RADIOISOTOPES
NEOPLASMS
NUCLEI
NUCLEOSIDES
NUCLEOTIDES
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
PATIENTS
POSITRON COMPUTED TOMOGRAPHY
PYRIMIDINES
RADIOISOTOPES
RIBOSIDES
THYMIDINE
TISSUE DISTRIBUTION
TOMOGRAPHY
UPTAKE
62 RADIOLOGY AND NUCLEAR MEDICINE
AZINES
BETA DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
CARBON 11
CARBON ISOTOPES
CELL PROLIFERATION
COMPUTERIZED TOMOGRAPHY
DIAGNOSIS
DIAGNOSTIC TECHNIQUES
DISEASES
DISTRIBUTION
EMISSION COMPUTED TOMOGRAPHY
EVEN-ODD NUCLEI
HETEROCYCLIC COMPOUNDS
IMMUNE SYSTEM DISEASES
IN VIVO
ISOTOPES
LIGHT NUCLEI
LYMPHOMAS
MINUTES LIVING RADIOISOTOPES
NEOPLASMS
NUCLEI
NUCLEOSIDES
NUCLEOTIDES
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
PATIENTS
POSITRON COMPUTED TOMOGRAPHY
PYRIMIDINES
RADIOISOTOPES
RIBOSIDES
THYMIDINE
TISSUE DISTRIBUTION
TOMOGRAPHY
UPTAKE